TINs Webinar: Therapeutic applications of humanized antibodies

During this webinar, Professor Stephen Moss explored the reasons behind choosing this modality and the steps involved in progressing a few hopeful ideas into something ready to inject into patients. He will also relate his own experience of this journey that resulted in the development of Magacizumab, an antibody that blocks the activity of leucine-rich a-2-glycoprotein 1, with a range of therapeutic applications.This is part of the webinar series by the UCL Therapeutic Innovation Networks (TINs) to highlight UCL’s Research Infrastructure and Capabilities that enable effective translation of products toward patient/public benefit. The series aims to encourage multidisciplinary collaborations across departments. Academics from the UCL biomedical community are invited to share subjects of interest from their research expertise and interact with research fellows.